Harnessing anticalin technology as a multi-targeted treament approach for vision loss

糖尿病是世界范围内视力丧失和失明的主要原因，是由两种叫做VEGF和Ang2的因素引起的，这两种因素会损害血管。目前的治疗方法只能阻断VEGF，许多患者没有反应，并遭受不可逆的视力损害。我们已经使用突破性的抗alin技术制造了一种新药（PRS-AUS1），它可以阻断VEGF和Ang2。研究将在动物模型中进行，并转移到患者身上，我们希望与目前的治疗方法相比，结果会有所改善。

Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.